CIAM
AVIR icon

Caitong International Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Caitong International Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11 Buy
+2
New +$9 ﹤0.01% 2132
2025
Q1 		– Sell
-479
Closed -$1.6K – 2172
2024
Q4 		$1.6K Buy
+479
New +$1.59K ﹤0.01% 1214

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Caitong International Asset Management's AVIR Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2026: 2 shares worth $11. The stake represents ﹤0.01% of the portfolio and ranks #2132 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in AVIR as recently as Q4 2024.

Caitong International Asset Management first reported a position in AVIR in Q4 2024 and has held it in 2 quarters since. The position peaked at $1.6K in Q4 2024. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Caitong International Asset Management held 2 shares of Atea Pharmaceuticals worth $11 as of Q1 2026.
  • Atea Pharmaceuticals was a new Caitong International Asset Management position in Q1 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2132 holding.
  • Caitong International Asset Management first reported a position in Atea Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • Caitong International Asset Management's Atea Pharmaceuticals position peaked at $1.6K in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.